The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo.
Although the N-terminal BOX-I domain of the tumor suppressor protein p53 contains the primary docking site for MDM2, previous studies demonstrated that RNA stabilizes the MDM2.p53 complex using a p53 mutant lacking the BOX-I motif. In vitro assays measuring the specific activity of MDM2 in the ligand-free and RNA-bound state ... identified a novel MDM2 interaction site in the core domain of p53. As defined using phage-peptide display, the RNA.MDM2 isoform exhibited a notable switch in peptide binding specificity, with enhanced affinity for novel peptide sequences in either p53 or small nuclear ribonucleoprotein-U (snRNP-U) and substantially reduced affinity for the primary p53 binding site in the BOX-I domain. The consensus binding site for the RNA.MDM2 complex within p53 is SGXLLGESXF, which links the S9-S10 beta-sheets flanking the BOX-IV and BOX-V motifs in the core domain and which is a site of reversible conformational flexibility in p53. Mutation of conserved amino acids in the linker at Ser(261) and Leu(264), which bridges the S9-S10 beta-sheets, stimulated p53 activity from reporter templates and increased MDM2-dependent ubiquitination of p53. Furthermore, mutation of the conserved Phe(270) within the S10 beta-sheet resulted in a mutant p53, which binds more stably to RNA.MDM2 complexes in vitro and which is strikingly hyper-ubiquitinated in vivo. Introducing an Ala(19) mutation into the p53(F270A) protein abolished both RNA.MDM2 complex binding and hyper-ubiquitination in vivo, thus indicating that p53(F270A) protein hyper-ubiquitination depends upon MDM2 binding to its primary site in the BOX-I domain. Together, these data identify a novel MDM2 binding interface within the S9-S10 beta-sheet region of p53 that plays a regulatory role in modulating the rate of MDM2-dependent ubiquitination of p53 in cells.
Mesh Terms:
Alleles, Amino Acid Motifs, Amino Acid Sequence, Binding Sites, Dose-Response Relationship, Drug, Genes, p53, Humans, Immunohistochemistry, Leucine, Ligands, Models, Molecular, Molecular Sequence Data, Mutation, Nuclear Proteins, Peptide Library, Precipitin Tests, Protein Binding, Protein Conformation, Protein Structure, Secondary, Protein Structure, Tertiary, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-mdm2, Sequence Homology, Amino Acid, Serine, Transcriptional Activation, Transfection, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Ubiquitin
Alleles, Amino Acid Motifs, Amino Acid Sequence, Binding Sites, Dose-Response Relationship, Drug, Genes, p53, Humans, Immunohistochemistry, Leucine, Ligands, Models, Molecular, Molecular Sequence Data, Mutation, Nuclear Proteins, Peptide Library, Precipitin Tests, Protein Binding, Protein Conformation, Protein Structure, Secondary, Protein Structure, Tertiary, Proto-Oncogene Proteins, Proto-Oncogene Proteins c-mdm2, Sequence Homology, Amino Acid, Serine, Transcriptional Activation, Transfection, Tumor Cells, Cultured, Tumor Suppressor Protein p53, Ubiquitin
J. Biol. Chem.
Date: Aug. 09, 2002
PubMed ID: 11925449
View in: Pubmed Google Scholar
Download Curated Data For This Publication
114702
Switch View:
- Interactions 2